Introduction {#sec1}
============

Gastric cancer (GC) is the fourth most common cancer and second leading cause of cancer-related deaths in the world, accounting for approximate 9% of total cancer deaths \[[@B1],[@B2]\]. Although the 5-year overall survival (OS) can reach more than 90% in early GC by early diagnosis and multi-disciplinary therapeutic strategies, the prognosis of advanced or metastatic GC patients remain largely unsatisfactory, with median survival period being around 1 year \[[@B3],[@B4]\]. Therefore, novel prognostic biomarkers for GC could contribute to the identification of those risky cases and maximize the OS benefits.

Signal transducers and activators of transcription (STATs) are a gene family of cytoplasmic transcription factors, consisting of seven members, STAT1--STAT4, STAT5a, STAT5b, and STAT6 \[[@B5],[@B6]\]. STATs play important roles in numerous biological processes, including cell proliferation, differentiation, apoptosis, and survival \[[@B7]\]. STATs are activated via tyrosine phosphorylation, a process which occurs either through KIT-based interaction or cytokine-induced JAK pathway \[[@B8]\]. STATs can also be activated by constitutively activated non-receptor protein tyrosine kinases (PTKs), including c-Src and Bcr-Abl. Activated STATs rapidly translocate into nucleus, and bind to the promoter region of target genes, serving as transcription regulators. Increasing evidence have indicated that the STATs, particularly STAT1, STAT3, and STAT5 play critical roles in various cancer progressions and have been identified as potential therapeutic targets \[[@B9]\]. Nevertheless, reports focusing on the relationship between GC and STATs remain limited \[[@B14]\]. In fact, the prognostic values of STATs family in GC patients are yet to be fully characterized.

In the present study, we comprehensively explored the prognostic values of seven STATs genes using the Kaplan--Meier (KM) plotter online database and multiple public available databases.

Materials and methods {#sec2}
=====================

KM plotter prognostic analysis {#sec2-1}
------------------------------

The prognostic values of STATs family (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6) in GC were investigated in KM Plotter, an online database (<http://kmplot.com/analysis/>) providing prognostic evaluation of selected genes on breast, ovarian, lung, and GC patients \[[@B17]\]. Corresponding GC datasets used in KM plotter were retrieved from Gene Expression Omnibus (GEO), including GSE14210, GSE15459, GSE22377, GSE29272, GSE51105 and GSE62254. In addition, differentiation, human epidermal growth factor receptor 2 (HER2) status, Lauren classification, and TNM stage data were also obtained for subtype analysis. Briefly, the cutoff values for individual STAT genes expression between 'low' and 'high' were determined by optimal cutoff algorithm. The prognostic values between high and low expression groups were evaluated by a KM curve with hazard ratio (HR), 95% confidence intervals (CI), and log-rank *P*-value. *P*-value \<0.05 was considered to be statistically significant.

Prognostic values of STATs signature via the SurvExpress platform {#sec2-2}
-----------------------------------------------------------------

The prognostic values of STATs signature were explored via the SurvExpress platform (<http://bioinformatica.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp>) with the stomach adenocarcinoma (STAD) of the cancer genome atlas (TCGA) selected as input dataset (*n*=352) \[[@B18]\]. High/low risk groups were categorized based on the default prognostic risk algorithm \[[@B18]\].

Oncomine database analysis {#sec2-3}
--------------------------

The mRNA expression of STATs members was investigated via the Oncomine database, which was a comprehensive cancer genomic platform \[[@B19]\]. Briefly, the mRNA expression of each STAT gene was compared between cancer and normal groups with *P-*value \<0.05 set as statistically significant. Only significant results were displayed.

Tumor immune infiltrating cells (TIICs) correlation analysis {#sec2-4}
------------------------------------------------------------

The correlations between each STAT and tumor immune infiltrating cells (TIICs) (B cells, CD4^+^ T cells, CD8^+^ T cells, dendritic cells, macrophages, and neutrophils) were analyzed via the Tumor IMmune Estimation Resource (TIMER) platform (<https://cistrome.shinyapps.io/timer/>) \[[@B20]\]. The correlation was further corrected by the tumor purity-based Spearman's method \[[@B20]\].

Results {#sec3}
=======

Prognostic values of STATs in all GC patients {#sec3-1}
---------------------------------------------

The prognostic values of STATs in all GC were investigated via the KM plotter. Among seven STATs members, five were significantly associated with prognosis for all GC patients ([Figure 1](#F1){ref-type="fig"}A). High mRNA expression of STAT1 (HR: 0.71; 95% CI: 0.57--0.89; *P*=0.0025), STAT2 (HR: 0.75; 95% CI: 0.57--1; *P*=0.05), STAT4 (HR: 0.76; 95% CI: 0.61--0.94; *P*=0.013), STAT5a (HR: 0.81; 95% CI: 0.66--1; *P*=0.05), and STAT5b (HR: 0.81; 95% CI: 0.67--0.98; *P*=0.029) were associated with better OS ([Figure 1](#F1){ref-type="fig"}B--F). STAT6 (HR: 0.82; 95% CI: 0.66--1.02; =0.076) and STAT3 (HR: 1.21; 95% CI: 0.89--1.65; *P*=0.23) did not show significant prognostic values ([Figure 1](#F1){ref-type="fig"}A).

![The prognostic values of individual STATs mRNA level in all GC patients\
(**A**) Forest plot for the relationship between individual STATs mRNA expression and prognostic OS in all GC patients. OS curves of (**B**) STAT1 (Affymetrix ID: 200887_s\_at), (**C**) STAT2 (Affymetrix ID: 225636 \_at), (**D**) STAT4 (Affymetrix ID: 206118 \_at), (**E**) STAT5a (Affymetrix ID: 203010 \_at), and (**F**) STAT5b (Affymetrix ID: 212549 \_at) are plotted for all GC patients.](bsr-39-bsr20181695-g1){#F1}

Prognostic values of STATs in HER2 subtypes {#sec3-2}
-------------------------------------------

Next, the prognostic values of STATs associated with the HER2 subtypes in GC patients were explored ([Figure 2](#F2){ref-type="fig"}). High mRNA expression of STAT1, STAT5a, and STAT5b were associated with better OS in HER2-negative GC patients ([Figure 2](#F2){ref-type="fig"}). Meanwhile, high expression of STAT4 and STAT6 were associated with better OS in HER2-positive GC patients. STAT5a was modestly associated with favorable OS in HER2-positive GC patients ([Figure 2](#F2){ref-type="fig"}). The rest STAT members were not significantly correlated with prognosis.

![The prognostic values of individual STATs mRNA level with HER2 gene\
OS curves of (**A**) STAT1, (**B**) STAT5a, and (**C**) STAT5b are plotted in GC patients with HER2-negative gene. OS curves of (**D**) STAT4, (**E**) STAT5a, and (**F**) STAT6 (Affymetrix ID: 201331_s\_at) are plotted in GC patients with HER2-positive gene.](bsr-39-bsr20181695-g2){#F2}

Prognostic values of STATs in GC patients with Lauren's classification {#sec3-3}
----------------------------------------------------------------------

High mRNA expression of STAT2, STAT4, STAT5b, and STAT6 were associated with favorable OS in the diffuse type of GC patients ([Figure 3](#F3){ref-type="fig"}A--D). High expression of STAT1, STAT3, and STAT6 mRNA expression in intestinal type GC patients were significantly associated with unfavorable OS, while STAT2 was modestly associated with unfavorable OS ([Figure 3](#F3){ref-type="fig"}E--H). High expression of STAT1 mRNA was associated with favorable OS in mixed type GC patient whereas STAT5a and STAT6 were associated with unfavorable OS ([Figure 3](#F3){ref-type="fig"}I--K).

![The prognostic values of individual STATs mRNA level in GC with histological subtypes according to Lauren's classification\
OS curves of (**A**) STAT2, (**B**) STAT4, (**C**) STAT5b, and (**D**) STAT6 are plotted for diffuse type GC patients. OS curves of (**E**) STAT1, (**F**) STAT2, (**G**) STAT3 (Affymetrix ID: 225289 \_at), and (**H**) STAT6 are plotted for intestinal type GC patients. OS curves of (**I**) STAT1, (**J**) STAT5a, and (**K**) STAT6 are plotted for mixed-type GC patients.](bsr-39-bsr20181695-g3){#F3}

Prognostic values of STATs in GC patients with differentiation subtypes {#sec3-4}
-----------------------------------------------------------------------

High mRNA expression of STAT1 and STAT2 were associated with unfavorable prognosis in moderately differentiated type GC, but with favorable prognosis in poorly differentiated type GC ([Figure 4](#F4){ref-type="fig"}A--D). High expression of STAT6 was associated with unfavorable OS in poorly differentiated type GC ([Figure 4](#F4){ref-type="fig"}E).

![The prognostic values of individual STATs mRNA level in GC patients with various differentiation\
OS curves of (**A**) STAT1 and (**B**) STAT2 are plotted for moderately differentiated type GC patients. OS curves of (**C**) STAT1, (**D**) STAT2, and (**E**) STAT6 are plotted for poorly differentiated type GC patients.](bsr-39-bsr20181695-g4){#F4}

Prognostic values of STATs in different GC clinical stages {#sec3-5}
----------------------------------------------------------

Only high expression of STAT4 was associated with worse prognosis in stage I in GC patients ([Table 1](#T1){ref-type="table"}). In stage III, high expression of STAT1, STAT2, and STAT4 were associated with favorable OS, while STAT5b was associated with poor OS ([Table 1](#T1){ref-type="table"}). None of the STAT members were found to be correlated with OS in stages II and IV. In addition, high expression of STAT6 was associated with worse prognosis in lymph node-negative GC. For lymph node-positive GC, STAT1 and STAT3 were associated with worse survival, whereas STAT4 was associated with better OS ([Table 1](#T1){ref-type="table"}). High level of STAT1 mRNA expression was associated with worse prognosis both in M0 and M1 stage GC patients whereas STAT3 was associated with poor OS in M0 stage ([Table 1](#T1){ref-type="table"}).

###### Prognostic correlation of STATs mRNA expression in GC patients with different clinical stage

  Clinical stage   STATs    Cases   HR (95% CI)          *P*-value
  ---------------- -------- ------- -------------------- ------------------------------------------
  Stage I                                                
                   STAT1    39      0.63 (0.21--1.88)    0.4
                   STAT2    34      0.4 (0.08--1.95)     0.24
                   STAT3    34      0.34 (0.07--1.61)    0.15
                   STAT4    39      4.32 (1.41--13.21)   0.0055[\*](#T1TFN1){ref-type="table-fn"}
                   STAT5a   39      0.37 (0.12--1.17)    0.079
                   STAT5b   39      0.41 (0.12--1.35)    0.13
                   STAT6    39      2.24 (0.74--6.8)     0.14
  Stage II                                               
                   STAT1    49      2.45 (0.72--8.36)    0.14
                   STAT2    44      0.48 (0.14--1.67)    0.24
                   STAT3    44      2.17 (0.49--9.55)    0.3
                   STAT4    49      0.5 (0.21--1.17)     0.1
                   STAT5a   49      1.58 (0.67--3.71)    0.29
                   STAT5b   49      1.69 (0.57--4.99)    0.34
                   STAT6    49      2.53 (0.74--8.69)    0.13
  Stage III                                              
                   STAT1    217     0.61 (0.41--0.9)     0.011[\*](#T1TFN1){ref-type="table-fn"}
                   STAT2    109     0.62 (0.39--1)       0.05[\*](#T1TFN1){ref-type="table-fn"}
                   STAT3    109     0.82 (0.52--1.3)     0.4
                   STAT4    217     0.64 (0.43--0.94)    0.021[\*](#T1TFN1){ref-type="table-fn"}
                   STAT5a   217     0.87 (0.6--1.24)     0.43
                   STAT5b   217     1.41 (1.02--1.94)    0.035[\*](#T1TFN1){ref-type="table-fn"}
                   STAT6    217     1.13 (0.82--1.56)    0.45
  Stage IV                                               
                   STAT1    74      1.38 (0.8--2.41)     0.25
                   STAT2    66      0.64 (0.32--1.27)    0.2
                   STAT3    66      1.65 (0.87--3.13)    0.12
                   STAT4    74      0.63 (0.33--1.19)    0.15
                   STAT5a   74      1.29 (0.75--2.23)    0.36
                   STAT5b   74      0.79 (0.46--1.37)    0.4
                   STAT6    74      0.74 (0.42--1.32)    0.31
  LN (--)                                                
                   STAT1    38      3.34 (0.75--14.78)   0.092
                   STAT2    38      2.15 (0.78--5.94)    0.13
                   STAT3    38      0.57 (0.21--1.56)    0.27
                   STAT4    38      0.53 (0.19--1.46)    0.21
                   STAT5a   38      0.42 (0.12--1.5)     0.17
                   STAT5b   38      1.72 (0.64--4.6)     0.28
                   STAT6    38      2.73 (0.99--7.57)    0.045[\*](#T1TFN1){ref-type="table-fn"}
  LN (+)                                                 
                   STAT1    175     1.78 (1.15--2.75)    0.0083[\*](#T1TFN1){ref-type="table-fn"}
                   STAT2    175     0.68 (0.44--1.05)    0.082
                   STAT3    175     1.72 (1.14--2.6)     0.0095[\*](#T1TFN1){ref-type="table-fn"}
                   STAT4    175     0.64 (0.44--0.94)    0.023[\*](#T1TFN1){ref-type="table-fn"}
                   STAT5a   175     0.77 (0.52--1.14)    0.19
                   STAT5b   175     0.78 (0.53--1.15)    0.22
                   STAT6    175     1.42 (0.92--2.17)    0.11
  M0                                                     
                   STAT1    186     1.74 (1.11--2.73)    0.015[\*](#T1TFN1){ref-type="table-fn"}
                   STAT2    186     0.72 (0.45--1.15)    0.16
                   STAT3    186     1.62 (1.05--2.5)     0.027[\*](#T1TFN1){ref-type="table-fn"}
                   STAT4    186     0.67 (0.44--1)       0.051
                   STAT5a   186     0.7 (0.47--1.03)     0.068
                   STAT5b   186     0.69 (0.46--1.03)    0.066
                   STAT6    186     1.3 (0.88--1.92)     0.19
  M1                                                     
                   STAT1    31      3.86 (1.38--10.84)   0.0064[\*](#T1TFN1){ref-type="table-fn"}
                   STAT2    31      2.37 (0.87--6.44)    0.082
                   STAT3    31      1.85 (0.76--4.48)    0.17
                   STAT4    31      2.8 (0.94--8.4)      0.056
                   STAT5a   31      0.54 (0.23--1.31)    0.17
                   STAT5b   31      1.42 (0.59--3.44)    0.43
                   STAT6    31      2.33 (0.92--5.89)    0.066

*P*\<0.05.

The prognostic value of STATs signature {#sec3-6}
---------------------------------------

Intriguingly, low risk group displayed a significantly favorable OS than high risk (HR: 1.71; 95% CI: 1.09--2.66, *P*=0.0184) ([Figure 5](#F5){ref-type="fig"}C), indicating potential prognostic role of STATs signature in GC. Of note, STAT5B showed the most up-regulated expression in high risk compared with low risk ([Figure 5](#F5){ref-type="fig"}A, B).

![The prognostic values of STATs signature\
(**A**) Expression heat map between low (green, *n*=305) and high (red, *n*=47) risk groups; (**B**) expression comparison between low and high risk groups; (**C**) the survival analysis between low and high risk groups.](bsr-39-bsr20181695-g5){#F5}

The mRNA expression analysis of STATs in GC {#sec3-7}
-------------------------------------------

The expression levels of STATs have been investigated via the Oncomine database. Intriguingly, compared with normal group, STATs showed distinct expression not only in general GC, but also in Laurens subtypes (intestinal, mixed, and diffuse types) and pathological types (papillary adenocarcinoma and tubular adenocarcinoma) ([Table 2](#T2){ref-type="table"}).

###### Comparison of transcription expression of STATs family members between different subtypes of GC and normal tissues via Oncomine

  STAT members   Types of GC vs normal (N)               *P*-value   *T*-test   Fold change   Resources
  -------------- --------------------------------------- ----------- ---------- ------------- ------------
  STAT1          Intestinal type vs N                    6.96E-15    9.751      2.703         \[[@B21]\]
                 Mixed type vs N                         1.34E-04    5.291      2.449         \[[@B21]\]
                 GC vs N                                 5.48E-05    3.971      1.348         \[[@B22]\]
                 Intestinal type vs N                    0.002       3.081      1.881         \[[@B23]\]
                 Diffuse type vs N                       0.005       2.711      1.656         \[[@B23]\]
                 Diffuse type vs N                       0.006       3.282      1.854         \[[@B24]\]
                 Intestinal type vs N                    2.45E-06    5.146      1.996         \[[@B24]\]
                 Mixed type vs N                         0.006       4.459      5.034         \[[@B24]\]
                 Intestinal type vs N                    0.026       2.006      1.026         \[[@B19]\]
                 Gastric adenocarcinoma vs N             2.84E-04    3.627      1.035         \[[@B25]\]
                 Diffuse type vs N                       0.008       2.501      1.016         \[[@B25]\]
                 GC vs N                                 0.03        1.972      1.572         \[[@B26]\]
  STAT2          Gastric papillary adenocarcinoma vs N   0.012       6.116      1.017         \[[@B19]\]
                 Gastric tubular adenocarcinoma vs N     0.012       2.375      1.053         \[[@B19]\]
                 GC vs N                                 8.55E-09    5.946      1.411         \[[@B22]\]
                 Diffuse type vs N                       0.005       2.81       1.389         \[[@B21]\]
                 Mixed type vs N                         0.016       2.336      1.468         \[[@B21]\]
                 Intestinal type vs N                    0.002       3.137      1.458         \[[@B21]\]
                 GC vs N                                 1.42E-04    3.949      1.039         \[[@B25]\]
                 Mixed type vs N                         0.039       1.964      1.05          \[[@B25]\]
                 Gastric adenocarcinoma vs N             2.96E-04    3.598      1.023         \[[@B25]\]
                 Diffuse type vs N                       0.001       3.223      1.013         \[[@B25]\]
                 Intestinal type vs N                    0.025       2.026      1.019         \[[@B25]\]
                 GC vs N                                 0.005       2.786      1.403         \[[@B26]\]
                 Mixed type vs N                         0.017       3.09       1.642         \[[@B24]\]
  STAT3          Mixed type vs N                         6.45E-06    7.834      2.19          \[[@B24]\]
                 Diffuse type vs N                       4.08E-04    5.117      2.096         \[[@B24]\]
                 Intestinal type vs N                    2.26E-10    7.653      2.252         \[[@B24]\]
                 GC vs N                                 0.002       2.909      1.203         \[[@B22]\]
                 GC vs N                                 0.002       3.175      1.348         \[[@B26]\]
                 Diffuse type vs N                       0.001       3.171      1.303         \[[@B23]\]
                 Intestinal type vs N                    0.048       1.709      1.167         \[[@B23]\]
                 Intestinal type vs N                    2.20E-04    3.675      1.231         \[[@B21]\]
                 GC vs N                                 0.007       2.55       1.026         \[[@B25]\]
                 Gastric adenocarcinoma vs N             0.01        2.39       1.019         \[[@B25]\]
  STAT4          Intestinal type vs N                    0.026       2.006      1.026         \[[@B19]\]
                 Gastric adenocarcinoma vs N             2.05E-04    3.727      1.034         \[[@B25]\]
                 Diffuse type vs N                       0.008       2.501      1.016         \[[@B25]\]
  STAT5a         Mixed type vs N                         4.53E-04    5.012      2.563         \[[@B24]\]
                 GC vs N                                 0.002       3.238      1.483         \[[@B26]\]
                 GC vs N                                 0.033       1.855      1.277         \[[@B22]\]
                 Intestinal type vs N                    0.047       1.727      1.247         \[[@B23]\]
                 Diffuse type vs N                       0.042       1.765      1.204         \[[@B23]\]
                 GC vs N                                 0.007       2.55       1.026         \[[@B25]\]
                 Gastric adenocarcinoma vs N             0.01        2.39       1.019         \[[@B25]\]
  STAT5b         Mixed type vs N                         5.59E-04    5.007      2.895         \[[@B24]\]
                 Intestinal type vs N                    2.63E-05    4.318      1.24          \[[@B21]\]
                 Mixed type vs N                         0.009       2.711      1.225         \[[@B21]\]
                 Diffuse type vs N                       0.017       2.262      1.166         \[[@B21]\]
                 GC vs N                                 0.003       3.07       1.728         \[[@B26]\]
                 Gastric adenocarcinoma vs N             0.043       1.723      1.017         \[[@B19]\]
                 GC vs N                                 0.007       2.55       1.026         \[[@B25]\]
                 Gastric adenocarcinoma vs N             0.014       2.239      1.019         \[[@B25]\]
  STAT6          Gastric papillary adenocarcinoma vs N   0.012       6.122      1.017         \[[@B19]\]
                 Gastric tubular adenocarcinoma vs N     0.012       2.376      1.053         \[[@B19]\]
                 GC vs N                                 1.42E-04    3.949      1.039         \[[@B25]\]
                 Gastric adenocarcinoma vs N             1.65E-04    3.775      1.024         \[[@B25]\]
                 Diffuse type vs N                       0.001       3.223      1.013         \[[@B25]\]
                 Mixed type vs N                         0.004       3.102      1.861         \[[@B24]\]
                 Intestinal type vs N                    0.026       1.988      1.536         \[[@B24]\]

The correlation analysis between STATs and TIICs {#sec3-8}
------------------------------------------------

Noteworthy, the highest correlations were found in STAT4 versus dendritic cell (correlation = 0.716, *P*=1.63e-59), and STAT4 versus CD8^+^ T cells (correlation = 0.697, *P*=5.02e-55). Meanwhile, six correlations were found above 0.5, including STAT4 versus neutrophil cell (correlation = 0.622, *P*=4.61e-41), STAT5A versus dendritic cell (correlation = 0.543, *P*=8.07e-30), STAT5B versus CD4^+^ T cell (correlation = 0.606, *P*=5.33e-38), STAT5B versus macrophage cell (correlation = 0.521, *P*=4.42e-27), STAT2 versus neutrophil cell (correlation = 0.509, *P*=7.42e-26) and STAT2 versus dendritic cell (correlation = 0.521, *P*=3.73e-27) ([Figure 6](#F6){ref-type="fig"}).

![Correlation of TIICs and STATs members\
B cells, CD4^+^ T cells, CD8^+^ T cells, neutrophils, macrophages, and dendritic cells were compared with the STATs regarding the expression correlation.](bsr-39-bsr20181695-g6){#F6}

Discussion {#sec4}
==========

STATs gene family have participated in diverse roles in carcinogenesis and tumor progression. In the present study, the prognostic roles of STATs members in GC patients were assessed through the KM plotter. High mRNA expression of STAT1, STAT2, STAT4, STAT5a, and STAT5b were significantly correlated to a favorable OS in GC patients.

Moreover, inverse prognostic values of STAT1, STAT2, and STAT6 were found between Lauren's subtypes. Meanwhile, we also observed inverse prognostic values of STAT1 and STAT2 between the moderately and poorly differentiated subtypes. Several reasons may hold accountable. First, comparable smaller sample size in subtype analysis may be a confounding bias factor in prognosis evaluation, particularly in mixed subtype of STAT1 (*n*=25), STAT6 (*n*=25). Second, both Lauren's classification and differentiation represent key pathological features of GC, in which molecular features are yet to be fully disclosed. Distinct prognostic values between each subtype in the present study may contribute to deeper knowledge of the pathological keys in GC. Third, the inverse prognostic values open up a new question as whether STATs may have opposite roles in each subtype.

Several studies had reported that STAT1 plays a role in gastric inflammation and tumorigenesis in mice model \[[@B27],[@B28]\]. But so far, studies about STAT1 and prognosis in GC are limited. Deng *et al.* \[[@B29]\] indicated that STAT1 mRNA was related to favorable prognosis in GC. Our results revealed that high expression of STAT1 mRNA was associated with a better OS in all GC patients. This result is in line with previous result. Stage specifically, we observed that high mRNA expression of STAT1 indicated a better OS in stage III. Collectively, our study suggested that STAT1 may be a prognosis predictor especially for late stage and poorly differentiated GC patients.

The role of STAT2 in GC remains limited. In the current study, we found that high STAT2 mRNA level was associated with favorable OS. Similar to STAT1, high STAT2 mRNA expression was associated with better OS in poorly differentiated and stage III GC patients.

STAT3, activated by tyrosine phosphorylation in response to growth factors and cytokines, was mainly involved in the oncogenesis of several human cancers, including GC \[[@B30],[@B31]\]. Previous studies showed the relationship between STAT3 mRNA expression and the prognosis in GC patients. However, controversies remained. Some studies \[[@B14],[@B32]\] indicated that elevated STAT3 mRNA expression was associated with poor outcomes in GC patients. Nonetheless, Woo *et al.* \[[@B37]\] reported that the overexpression of STAT3 was correlated with favorable outcome of patients with GC. Nevertheless, Xiong *et al.* \[[@B38]\] and Lee *et al.* \[[@B39]\] showed no correlation between high STAT3 mRNA expression and OS. Interestingly, our data found there was no significant correlation between STAT3 mRNA expression and OS of GC patients. This can be attributed to different study design, race diversity, clinical stage, sample size, and cutoff definition. Moreover, Chatterjee *et al.* \[[@B34]\] showed that STAT3 expression was associated with poor prognosis in the intestinal subtype, consistent with our findings. Furthermore, Deng *et al.* \[[@B35]\] and Kim *et al.* \[[@B16]\] demonstrated that high STAT3 expression was significantly associated with lymph node invasion, which was consistent with our results that high STAT3 mRNA level was significant associated with unfavorable OS. The present study also indicated that STAT3 mRNA expression was correlated to poor prognosis in M0 stage GC patients. Collectively, although STAT3 showed no effect on OS, but it remained a potential prognostic predictor in subtypes of GC.

Similar to STAT2, studies about STAT4 and its prognosis in GC patients are limited. Nishi *et al.* \[[@B40]\] indicated that high STAT4 expression was associated with better disease free survival in GC. Our results revealed that high STAT4 mRNA expression was significantly associated with better OS for all GC patients, subtypes in HER2-positive, diffuse subtype, stage III, and lymph node-positive GC.

STAT5 is consisted of two highly homologous genes, STAT5a and STAT5b \[[@B41]\]. In GC, Kim *et al.* \[[@B16]\] reported that STAT5 had no statistical significance in the analysis of survival. However, our results suggested that high mRNA expression STAT5a and STAT5b were significantly associated with better OS.

So far, studies focusing on the prognostic value of STAT6 expression in malignancies, especially GC, remain limited. In the present study we found that high STAT6 mRNA level was not significantly associated with OS.

The present study has some limitations, including lack of experimental and clinical validations to confirm the prognostic values of STATs in GC, as well as comparably small sample size in some subtypes analysis. More studies with large sample size are warranted to validate the prognostic value of STATs family.

Conclusion {#sec5}
==========

The present study showed that high mRNA expression of STATs except STAT3 and STAT6 were significantly correlated to favorable OS in GC patients.
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